Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
[ad_1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
Lu CD, Adeyemi O, Anderson WE, Hetherington TC, Slawson DC, Tapp H, et al. Racial disparities in prostate specific antigen screening and referral to urology in a large, integrated health care system: a retrospective cohort study. J Urol. 2021;206:270–8.
Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28:1069–74.
Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, et al. Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs Health Care System. JAMA Netw Open. 2022;5:e2144027.
Chowdhury-Paulino IM, Ericsson C, Vince R, Jr, Spratt DE, George DJ, Mucci LA. Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis. 2021; https://doi.org/10.1038/s41391-021-00451-z.
Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of black race with prostate cancer–specific and other-cause mortality. JAMA Oncol. 2019;5:975–83.
Gordon BE, Basak R, Carpenter WR, Usinger D, Godley PA, Chen RC. Factors influencing prostate cancer treatment decisions for African American and white men. Cancer 2019;125:1693–700.
Bhardwaj A, Srivastava SK, Khan MA, Prajapati VK, Singh S, Carter JE, et al. Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed). 2017;22:772–82.
McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, et al. Tackling diversity in prostate cancer clinical trials: a report from the Diversity Working Group of the IRONMAN Registry. JCO Glob Oncol. 2021;7:495–505.
Wissing MD, Kluetz PG, Ning YM, Bull J, Merenda C, Murgo AJ, et al. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer 2014;120:3025–32.
George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsky J, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–94.
Lorente D, Fizazi K, Sweeney C, de Bono JS. Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus. 2016;2:488–98.
Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021;519:20–9.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
National Comprehensive Cancer Network. NCCN Prostate Cancer Guidelines (Version 3.2022). Accessed March 3, 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Fuerea A, Baciarello G, Patrikidou A, Albigès L, Massard C, Di Palma M, et al. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur J Cancer. 2016;61:44–51.
Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur Urol Oncol. 2019;2:677–84.
George DJ, Heath EI, Sartor AO, Sonpavde G, Berry WR, Healy P, et al. Abi Race: a prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). Abstract LBA5009. J Clin Oncol. 2018;36(18_suppl).
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, et al. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urol Oncol. 2017;35:418–24.
Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, et al. PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: a retrospective case-report study. Med (Baltim). 2017;96:e6817.
Cicero G, Luca RDE, Dorangricchia P, Dieli F. The clinical efficacy of enzalutamide in metastatic prostate cancer: prospective single-center study. Anticancer Res. 2017;37:1475–80.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.
Zhang Z, Kim HJ, Lonjon G, Zhu Y, written on behalf of AMEB-DCTCG. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16.
George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, et al. Survival by race in men with chemotherapy-naive enzalutamide-or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:525–30.
Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. Outcomes among African American and non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open. 2022;5:e2142093.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl J Med. 2019;381:121–31.
Package Insert. XTANDI® (enzalutamide) capsules, for oral use. Northbrook, IL: Astellas Pharma US, Inc. 2014. Accessed June 3, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203415s003lbl.pdf.
Package Insert. XTANDI® (enzalutamide) capsules, for oral use. Northbrook, IL: Astellas Pharma US, Inc. 2012. Accessed October 25, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf.
Package Insert. XTANDI® (enzalutamide) capsules, for oral use. Northbrook, IL: Astellas Pharma US, Inc. 2018. Accessed March 3, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415Orig1s014lbl.pdf.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74.
Raju R, Sahu A, Klevansky M, Torres J. Real-world data on outcomes in metastatic castrate-resistant prostate cancer patients treated with abiraterone or enzalutamide: a regional experience. Front Oncol. 2021;11:656146.
McKay RR, Hafron JM, Ferro C, Wilfehrt HM, Fitch K, Flanders SC, et al. A retrospective observational analysis of overall survival with sipuleucel-T in Medicare beneficiaries treated for advanced prostate cancer. Adv Ther. 2020;37:4910–29.
Gajra A, Hime S, Jeune-Smith Y, Russell A, Feinberg BA. Referral patterns and treatment preferences in patients with advanced prostate cancer (aPC): differences between medical oncologists and urologists. J Clin Oncol. 2021;39:71.
[ad_2]
Source link
